GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis

Final oocyte maturation in gnrh antagonist co-treated ivf/icsi cycles can be triggered with hcg or a gnrh agonist. we conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of the final oocyte maturation trigger in gnrh antagonist co-treated cycles. outcome measures were ongoing pregnancy rate (opr) and ovarian hyperstimulation syndrome (ohss) incidence. searches: were conducted in medline,embase,science direct,cochrane library,and databases of abstracts. there was a statistically significant difference against the gnrh agonist for opr in fresh autologous cycles (n=. 1024) with an odd ratio (or) of 0.69 (95% ci: 0.52-0.93). in oocyte-donor cycles (n=. 342) there was no evidence of a difference (or: 0.91; 95% ci: 0.59-1.40). there was a statistically significant difference in favour of gnrh agonist regarding the incidence of ohss in fresh autologous cycles (or: 0.06; 95% ci: 0.01-0.33) and donor cycles respectively (or: 0.06; 95% ci: 0.01-0.27). in conclusion gnrh agonist trigger for final oocyte maturation trigger in gnrh antagonist cycles is safer but less efficient than hcg. © 2015.